← Back to all products
How Do They Compare?
Understanding the difference between GLP-1, GIP, and GCG receptor agonists.
Semaglutide Ozempic / Wegovy | Tirzepatide Mounjaro / Zepbound | Retatrutide ✦ No brand name yet | |
|---|---|---|---|
| Receptors | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + GCG |
| Weight Loss | 15–18% | 20–22% | 24–25% |
| Key Benefit | Proven, stable | Dual synergy | Triple power |
| Efficacy | ⭐⭐⭐ | ⭐⭐⭐⭐ | ⭐⭐⭐⭐⭐ |
| Market Stage | Mature | Growth | Premium / Emerging |
| Clinical Data | Extensive | Strong | Promising |
Semaglutide
Ozempic / Wegovy
ReceptorsGLP-1
Weight Loss15–18%
Key BenefitProven, stable
Efficacy⭐⭐⭐
Market StageMature
Clinical DataExtensive
Tirzepatide
Mounjaro / Zepbound
ReceptorsGLP-1 + GIP
Weight Loss20–22%
Key BenefitDual synergy
Efficacy⭐⭐⭐⭐
Market StageGrowth
Clinical DataStrong
Retatrutide ✦
No brand name yet
ReceptorsGLP-1 + GIP + GCG
Weight Loss24–25%
Key BenefitTriple power
Efficacy⭐⭐⭐⭐⭐
Market StagePremium / Emerging
Clinical DataPromising
Why Each Matters
Semaglutide
Ozempic / Wegovy
Established safety & efficacy. Largest patient base worldwide.
Tirzepatide
Mounjaro / Zepbound
Superior results via dual GLP-1 + GIP pathway. Strong current momentum.
Retatrutide
No brand name yet
Next-generation breakthrough. Direct hepatic fat loss via GCG. First-to-market premium positioning.
TL;DR · More receptors = more weight loss. Retatrutide leads on efficacy, Semaglutide on track record, Tirzepatide on value.